295 related articles for article (PubMed ID: 32154663)
1. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Taarnhøj GA; Johansen C; Lindberg H; Basch E; Dueck A; Pappot H
Cancer Med; 2020 May; 9(9):3078-3087. PubMed ID: 32154663
[TBL] [Abstract][Full Text] [Related]
2. The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial.
Taarnhøj GA; Johansen C; Carus A; Dahlrot RH; Dohn LH; Hjøllund NH; Knudsen MB; Tolver A; Lindberg H; Pappot H
J Patient Rep Outcomes; 2023 Oct; 7(1):99. PubMed ID: 37812306
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
4. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study.
Taarnhøj GA; Lindberg H; Dohn LH; Omland LH; Hjøllund NH; Johansen C; Pappot H
Health Qual Life Outcomes; 2020 Jul; 18(1):225. PubMed ID: 32653005
[TBL] [Abstract][Full Text] [Related]
5. Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer.
Saranya K; Sreejith K; Ajaykumar
J Oncol Pharm Pract; 2019 Dec; 25(8):1853-1859. PubMed ID: 30616471
[TBL] [Abstract][Full Text] [Related]
6. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.
Taarnhøj GA; Kennedy FR; Absolom KL; Bæksted C; Vogelius IR; Johansen C; Velikova G; Pappot H
J Pain Symptom Manage; 2018 Sep; 56(3):421-429. PubMed ID: 29807157
[TBL] [Abstract][Full Text] [Related]
7. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
8. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
10. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.
Ripping TM; Rammant E; Witjes JA; Aaronson NK; van Hemelrijck M; van Hoogstraten LMC; ; Kiemeney LA; Aben KKH
Health Qual Life Outcomes; 2022 Dec; 20(1):171. PubMed ID: 36581934
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
12. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
O'Donnell PH; Arkenau HT; Sridhar SS; Ong M; Drakaki A; Spira AI; Zhang J; Gordon MS; Degboe AN; Gupta AK; Mukhopadhyay P; Huang W; Abdullah SE; Angra N; Roskos LK; Guo X; Friedlander T
Cancer; 2020 Jan; 126(2):432-443. PubMed ID: 31581306
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma.
Fukushi K; Narita T; Hatakeyama S; Yamamoto H; Soma O; Matsumoto T; Tobisawa Y; Yoneyama T; Imai A; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):366-372. PubMed ID: 27933402
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
Ferreira AR; Di Meglio A; Pistilli B; Gbenou AS; El-Mouhebb M; Dauchy S; Charles C; Joly F; Everhard S; Lambertini M; Coutant C; Cottu P; Lerebours F; Petit T; Dalenc F; Rouanet P; Arnaud A; Martin A; Berille J; Ganz PA; Partridge AH; Delaloge S; Michiels S; Andre F; Vaz-Luis I
Ann Oncol; 2019 Nov; 30(11):1784-1795. PubMed ID: 31591636
[TBL] [Abstract][Full Text] [Related]
18. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]